A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure

A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure

The purpose of this study is to test the effect of purified (acellular) amniotic fluid as a treatment for SARS CoV-2 (COVID19)-associated respiratory failure. Past use of human amniotic products (i.e., membrane and fluid) is FDA-approved for tissue injury and has been used to reduce inflammation and fibrosis in patients with a variety of medical conditions. The investigators hypothesize that using nebulized and/or intravenous purified (acellular) amniotic fluid will reduce both inflammation in patients hospitalized for in SARS CoV-2 (COVID19)-associated respiratory failure, potentially leading to a decrease in respiratory support.

Inclusion Criteria:

• 1. Age ≥18
• 2. Hospitalized and symptomatic (cough, fevers, SOB, or sputum production)
• 3. SARS CoV-2 laboratory positive obtained within 14 days of enrollment

Exclusion Criteria:

• 1. None